Spark Therapeutics Inc.
Visit Spark website

Spark Therapeutics was founded in 2013 and became a Member of the Roche Group in 2019.

The organisation is a fully integrated, commercial company committed to discovering, developing and delivering gene therapies for genetic diseases, including inherited retinal disorders, haemophilia, lysosomal storage disorders and neurodegenerative diseases.

Spark Therapeutics is comprised of over 800 employees with its headquarters situated in Philadelphia, USA.

More from the Roche Group

Get to know our structure

Discover more